Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand

被引:118
作者
Sukvirach, S
Smith, JS
Tunsakul, S
Muñoz, N
Kesararat, V
Opasatian, O
Chichareon, S
Kaenploy, V
Ashley, R
Meijer, CJLM
Snijders, PJF
Coursaget, P
Franceschi, S
Herrero, R
机构
[1] Int Agcy Res Canc, Unit Field & Intervent Studies, F-69372 Lyon 08, France
[2] Natl Canc Inst, Div Res, Bangkok, Thailand
[3] Prov Hlth Off, Lampang, Thailand
[4] Prince Songkla Univ, Hat Yai, Thailand
[5] Prov Hlth Off, Songkhla, Thailand
[6] INSERM, Mol Virol Lab, Tours, France
[7] Univ Washington, Seattle, WA 98195 USA
[8] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[9] Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
[10] Lampang Hosp, Lampang, Thailand
关键词
D O I
10.1086/373901
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To investigate the prevalence and determinants of human papillomavirus (HPV) infection, the primary cause of cervical cancer, we studied 1741 women greater than or equal to15 years of age from Lampang and Songkla, Thailand. Exfoliated cervical cells were collected for Papanicolaou smear screening and DNA detection of 36 different HPV types. Serum immunoglobulin G antibodies against L1 virus-like particles (anti-VLPs) of HPV-16, -18, -31, -33, and -58 were evaluated using enzyme-linked immunosorbent assay. Overall, 110 women (6.3%) were HPV DNA positive; the most common types were HPV-16, -52, and -72. The age-standardized prevalence of HPV DNA was higher among the 1035 women from Lampang (9.1%; 95% confidence interval [CI], 7.1-11.1) than among the 706 women from Songkla (3.9%; 95% CI, 2.3%-5.6%). Anti-VLPs were found in 21.8% of all women and were more frequent among women from Lampang (29.2%) than among women from Songkla (10.9%). Major risk factors for cervical HPV DNA were age <35 years, HSV-2 seropositivity, and having a husband with extramarital sexual partners.
引用
收藏
页码:1246 / 1256
页数:11
相关论文
共 54 条
[11]  
DEERASAMEE S, 1999, 34 INT AG RES CANC
[12]   A population-based five-year follow-up study of cervical human papillomavirus infection [J].
Elfgren, K ;
Kalantari, M ;
Moberger, B ;
Hagmar, B ;
Dillner, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (03) :561-567
[13]  
FERLAY J, 1998, 3 IARC
[14]  
Ferrera A, 1999, INT J CANCER, V82, P799, DOI 10.1002/(SICI)1097-0215(19990909)82:6&lt
[15]  
799::AID-IJC5&gt
[16]  
3.0.CO
[17]  
2-5
[18]   TRANSMISSION OF CERVICAL HUMAN PAPILLOMAVIRUS INFECTION BY SEXUAL-ACTIVITY - DIFFERENCES BETWEEN LOW AND HIGH ONCOGENIC RISK TYPES [J].
FRANCO, EL ;
VILLA, LL ;
RUIZ, A ;
COSTA, RC .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (03) :756-763
[19]   Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine [J].
Harro, CD ;
Pang, YYS ;
Roden, RBS ;
Hildesheim, A ;
Wang, ZH ;
Reynolds, MJ ;
Mast, TC ;
Robinson, R ;
Murphy, BR ;
Karron, RA ;
Dillner, J ;
Schiller, JT ;
Lowy, DR .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :284-292
[20]   Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica [J].
Herrero, R ;
Hildesheim, A ;
Bratti, C ;
Sherman, ME ;
Hutchinson, M ;
Morales, J ;
Balmaceda, I ;
Greenberg, MD ;
Alfaro, M ;
Burk, RD ;
Wacholder, S ;
Plummer, M ;
Schiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (06) :464-474